RECITALSExclusive Sublicense Agreement • May 10th, 2006 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus • Tennessee
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES...Exclusive Sublicense Agreement • September 22nd, 2011 • Coronado Biosciences Inc • Pharmaceutical preparations
This Exclusive Sublicense Agreement (hereinafter referred to as this “Agreement”), effective as of this December 12, 2005 (the “Effective Date”), is entered into by and between Ovamed GbmH & Co KG, a corporation duly incorporated under the laws of Germany and having a principal place of business at Kiebitzhörn 33-35, 22885 Barsbüttel, Germany (“Ovamed”) and Collingwood Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (the “Company”).
EXCLUSIVE SUBLICENSE AGREEMENT Between GERON CORPORATION and ASTERIAS BIOTHERAPEUTICS, INC.Exclusive Sublicense Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
This EXCLUSIVE SUBLICENSE AGREEMENT (the “Agreement”) is entered into as of October 1, 2013 (the “Effective Date”) by and between Geron Corporation, a Delaware corporation having a principal place of business at 149 Commonwealth Drive, Menlo Park, California 94025 (“Geron”), and Asterias Biotherapeutics, Inc., a Delaware corporation having a principal place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“Licensee”). Geron and Licensee are each referred to individually herein as a “Party,” and collectively as the “Parties.”
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • March 27th, 2007 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
This AGREEMENT (“Agreement”), dated November 7, 2006 (the “Effective Date”), is made by and between BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, IL 60069 (“BPA”), and Bradley Pharmaceuticals, Inc., 383 Route 46 West, Fairfield, New Jersey 07004-2402 (“Company”).
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • December 27th, 2010 • Iaso Pharma Inc • Pharmaceutical preparations • New York
This Exclusive Sublicense Agreement (hereinafter referred to as this “Agreement”), effective as July 10th, 2007 (the “Effective Date”), is entered into by and between SANTEE BIOSCIENCES, INC., a Delaware corporation (“Santee”), having a place of business at 4365 Executive Drive, Suite 1500, San Diego, California 92121, and PACIFIC BEACH BIOSCIENCES, INC., a Delaware corporation (“Pacific Beach”), having a place of business at 4365 Executive Drive, Suite 1500, San Diego, California 92121.
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • November 19th, 2008 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Exclusive Sublicense Agreement (“Agreement”) is made and entered into as of the 15th day of August, 2008 (the “Effective Date”), by and between Advanced Cell Technology, Inc., a Delaware corporation with offices located at 11100 Santa Monica Blvd, Suite 850, Los Angeles, CA 90025 (“ACT”), Embryome Sciences, Inc., a California corporation (“ES”), with offices located at 1301 Harbor Bay Parkway, Suite 100, Alameda, California 94502. ACT and ES are sometimes hereinafter referred to as the “Parties”.
Exclusive Sublicense Agreement in the PRC Territory by and among Razor Genomics, Inc. (“Sublicensor”), OncoCyte Corporation (“OncoCyte”), Encore Clinical, Inc. (“Encore”) and Burning Rock Biotech Limited (“Sublicensee”) dated December 14, 2020Exclusive Sublicense Agreement • December 16th, 2020 • OncoCyte Corp • In vitro & in vivo diagnostic substances
SIDE AMENDMENT TO PATENT AND KNOW-HOW EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • December 11th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations
This Side Amendment to patent and know-how exclusive sublicense Agreement (the “Side Agreement”) is entered into Friday, November 3, 2006 (“Effective Date”) by and among Immunodex, Inc., a California corporation having an address at 1230 H Street, Eureka, California, 95501 (“Immunodex”); The Cancer Research Institute of Contra Costa having an address at 1230 H Street, Eureka, CA 95501 (“CRICC”); and Somanta Incorporated (“Somanta”) having business addresses at 19200 Von Karman Avenue, Suite 400, Irvine, CA 92612 USA and 80 Harley Street, London, W1G 7HB, United Kingdom.
AMENDMENT NO. 2 TO EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • July 22nd, 2003 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances)
THIS AMENDMENT NO.2 to the exclusive sublicense agreement (the “Amendment”) is made and entered into as of May 29, 2003 by and between Alkermes, Inc., a Pennsylvania corporation with its principal offices at 64 Sydney Street, Cambridge, MA 02139 (hereinafter referred to as “Alkermes”), and Targeted Genetics Corporation, a Washington corporation with its principal offices at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (hereinafter referred to as “Targeted”).
CERTAIN INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS (“[***]”), HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD...Exclusive Sublicense Agreement • August 11th, 2022 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Exclusive Sublicense Agreement, made this 26th day of April, 2022 (the “Effective Date”), is by and between CLS Therapeutics LTD, a company organized under the laws of Guernsey with principal offices located at of PO Box 175, Frances House, Sir William Place, St Peter Port, Guernsey, GY1 4HQ, UK (“CLS”) and Xenetic Biosciences, Inc., a Nevada corporation, with offices located at 40 Speen St. Ste 102, Framingham, MA 01701 (“XBIO”). Each of XBIO and CLS may be referred to, individually, as a “Party”, and, collectively, as the “Parties”.
Exhibit 10.24 AMENDMENT NO. 1 TO EXCLUSIVE SUBLICENSE AGREEMENT This Amendment No. 1 is made to the Exclusive Sublicense Agreement made December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals, Inc., a New York corporation...Exclusive Sublicense Agreement • February 10th, 2006 • Biomimetic Therapeutics, Inc.
TEXT MARKED BY [ * * *] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • March 31st, 2011 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • Pennsylvania
This Exclusive Sublicense License Agreement (“Agreement”), dated as of May 28, 2010 (the “Effective Date”), is made by and between Targepeutics, Inc., a corporation organized under the laws of the State of Delaware (“TI”), having its principal office at 475 Governor Road, Hershey, PA 17033, and ImmunoCellular Therapeutics, Ltd., a Delaware corporation having its principal office at 21900 Burbank Boulevard, 3rd Floor, Woodland Hills, California 91367 (“SUBLICENSEE”).
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • November 9th, 2011 • Cleveland Biolabs Inc • Services-commercial physical & biological research • New York
This Exclusive Sublicense Agreement (“Agreement”) is made effective as of September 23, 2011 (“Effective Date”) by and between Cleveland BioLabs, Inc., a corporation organized and existing under the laws of the State of Delaware (“CBLI”), and Panacela, a corporation organized under the laws of the State of Delaware (“Panacela”). The parties hereto are additionally referred to individually as a “Party”, and collectively, the “Parties”.
AMENDMENT NO. 3 TO EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • March 29th, 2007 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 3 to the exclusive sublicense agreement (the “Amendment”) is made and entered into as of March 9, 2007 by and between Alkermes, Inc., a Pennsylvania corporation with its principal offices at 88 Sidney Street, Cambridge, MA 02139 (hereinafter referred to as “Alkermes”), and Targeted Genetics Corporation, a Washington corporation with its principal offices at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (hereinafter referred to as “Targeted”).
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • May 7th, 2013 • Synageva Biopharma Corp • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE SUBLICENSE AGREEMENT (the “Agreement”) is made and effective as of April 5, 2013 (the “Effective Date”) by and between Shire AG, a company organized under the laws of Switzerland, having a principal place of business at Business Park Terre-Bonne, Bâtiment A1, CH. De Terre Bonne 1,1262 Eysins, Switzerland (“Shire”), and Synageva BioPharma Corp., a Delaware corporation having a principal place of business at 128 Spring Street, Suite 520, Lexington, Massachusetts 02421, USA (“Synageva”). Shire and Synageva are referred to herein individually as a “Party” or collectively as the “Parties”.
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • May 15th, 2006 • Advanced Cell Technology, Inc. • Pharmaceutical preparations • Massachusetts
This Exclusive Sublicense Agreement (“Agreement”) is made and entered into as of March 29, 2006 (the “Effective Date”), by and between TranXenoGen, Inc., a Delaware corporation with offices located at 800 Boston Turnpike Rd, Shrewsbury, Massachusetts 01545 (“TXG”), and Advanced Cell Technology, Inc., a Delaware corporation with offices located at 1201 Harbor Bay Parkway, Suite 120, Alameda, California 94502 (“Licensee” or “ACT”) (TXG and Licensee sometimes hereinafter referred to as the “parties”, or individually as a “party”). As set forth below, Brandeis University (the “University”) agrees to be bound by certain provisions of this Agreement.
ContractExclusive Sublicense Agreement • November 12th, 2021 • POINT Biopharma Global Inc. • Pharmaceutical preparations
AMENDMENT NO. 1 TO AMENDED AND RESTATED EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • November 19th, 2010 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Amendment No. 1 (“Amendment No. 1”) to the Amended and Restated Exclusive Sublicense Agreement (“Agreement”) is entered into on November 1, 2010 (“Effective Date”) between BioMimetic Therapeutics, Inc. (“BMTI”), a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) and Luitpold Pharmaceuticals, Inc. (“Luitpold”), a New York corporation (each, individually, a “Party” and, collectively, the “Parties”).
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • August 24th, 2017 • Victory Energy Corp • Crude petroleum & natural gas • Texas
THIS EXCLUSIVE SUBLICENSE AGREEMENT (this “Agreement”) is made and entered into as of the 21st day of August, 2017 (the “Effective Date”), by and between ARMACOR VICTORY VENTURES, LLC, a Delaware limited liability company having its principal place of business at 20505 Crescent Bay Drive, Lake Forest, CA 92630 (“Licensor”), and VICTORY ENERGY CORPORATION, a Nevada corporation having its principal place of business at 3355 Bees Cave Road, Suite 608, Austin, TX 78746 (“Licensee”).
AMENDMENT NO. 4 TO EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • August 12th, 2009 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 4 (the “Amendment”) dated as of May 8, 2009 to the Exclusive Sublicense Agreement by and between Alkermes, Inc., a Pennsylvania corporation with its principal offices at 88 Sidney Street, Cambridge, MA 02139 (“Alkermes”), and Targeted Genetics Corporation, a Washington corporation with its principal offices at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (“Targeted”),
EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • June 1st, 2017 • Benitec Biopharma LTD/ADR • Pharmaceutical preparations • California
This Exclusive Sublicense Agreement (this “Agreement”) is made and entered into as of the 23rd day of December, 2016 (“Effective Date”), by and between Benitec Biopharma Limited, a company organized under the laws of Australia with its principal business at 99 Mount Street, North Sydney NSW 2060, Australia (“Benitec”), and NantWorks, LLC, a Delaware limited liability company with its principal business at 9920 Jefferson Boulevard, Culver City, California 90232 (“NantWorks”).
= Indicates confidential information omitted from the exhibit. 2. Except as herein specifically modified and amended herein, the Amended Agreement shall remain in full force and effect. In the event of any conflicts or discrepancies between the...Exclusive Sublicense Agreement • November 12th, 2021 • POINT Biopharma Global Inc. • Pharmaceutical preparations
ContractExclusive Sublicense Agreement • November 12th, 2021 • POINT Biopharma Global Inc. • Pharmaceutical preparations • Massachusetts
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • August 23rd, 2019 • Hoth Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Exclusive Sublicense Agreement (this “Agreement”) is made effective as of August 19, 2019 (the “Effective Date”) by and between Zylö Therapeutics, Inc., a Delaware corporation with a principal place of business at 200 Patewood Dr., Suite 400C, Greenville, SC 29615 (“Licensor”), and Hoth Therapeutics, Inc., a Nevada corporation with a place of business at 1 Rockefeller Plaza Suite 1039 New York, NY 10020 (“Licensee”). Licensor and Licensee are each hereafter referred to individually as a “Party” and together as the “Parties”.
ContractExclusive Sublicense Agreement • August 14th, 2023 • POINT Biopharma Global Inc. • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL
First Amendment to the Exclusive Sublicense AgreementExclusive Sublicense Agreement • August 14th, 2023 • POINT Biopharma Global Inc. • Pharmaceutical preparations
